Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

How conditioning intensity is related to outcomes of AML patients undergoing allografting in morphologic remission is an area of great ongoing interest. We studied 743 patients in morphologic remission and known pre-transplant measurable residual disease (MRD) status determined by multiparameter flow cytometry (MFC) who received a first allograft after myeloablative, reduced intensity, or nonmyeloablative conditioning (MAC, RIC, and NMA). Overall, relapse-free survival (RFS) and overall survival (OS) were longer after MAC than RIC or NMA conditioning, whereas relapse risks were not different. Among MRDpos patients, 3-year estimates of relapse risks and survival were similar across conditioning intensities. In contrast, among MRDneg patients, 3-year RFS and OS were longer for MAC (69% and 71%) than RIC (47% and 55%) and NMA conditioning (47% and 52%). Three-year relapse risks were lowest after MAC (18%) and highest after NMA conditioning (30%). Our data indicate an interaction between conditioning intensity, MFC-based pre-transplant MRD status, and outcome, with benefit of intensive conditioning primarily for patients transplanted in MRDneg remission. Differing from recent findings from other studies that indicated MAC is primarily beneficial for some or all patients with MRDpos pre-HCT status, our data suggest MAC should still be considered for MRDneg AML patients if tolerated.

[1]  B. Wood,et al.  Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach , 2020, Current protocols in cytometry.

[2]  B. Wood,et al.  Impact of Pre-Transplant Measurable Residual Disease on Outcome of Allogeneic Hematopoietic Cell Transplantation in Adult Monosomal Karyotype AML , 2020, Leukemia.

[3]  H. Deeg,et al.  Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Wood,et al.  Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease , 2019, Leukemia.

[5]  H. Deeg,et al.  Comparative Analysis of Total Body Irradiation (TBI)-Based and Non-TBI-Based Myeloablative Conditioning for Acute Myeloid Leukemia in Remission with and without Measurable Residual Disease , 2019, Blood.

[6]  E. Estey,et al.  Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia , 2019, Bone Marrow Transplantation.

[7]  Michael Stadler,et al.  Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. , 2018, Blood.

[8]  Torsten Haferlach,et al.  Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. , 2018, Blood.

[9]  C. Hourigan,et al.  Measurable residual disease testing in acute myeloid leukaemia , 2017, Leukemia.

[10]  E. Leifer,et al.  Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[12]  B. Wood,et al.  Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis , 2017, Haematologica.

[13]  E. Estey,et al.  Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[15]  M. Linden,et al.  Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  E. Estey,et al.  Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia , 2016, Leukemia.

[17]  M. Sorror,et al.  Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  B. Wood,et al.  Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation , 2013, Leukemia.

[19]  E. Estey,et al.  Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. , 2013, Blood.

[20]  L. Shaffer,et al.  Cytogenetic Nomenclature: Changes in the ISCN 2013 Compared to the 2009 Edition , 2013, Cytogenetic and Genome Research.

[21]  R. Schlenk,et al.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach , 2012, Nature Reviews Clinical Oncology.

[22]  R. Gale,et al.  SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS , 2011, Bone Marrow Transplantation.

[23]  E. Estey,et al.  Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[25]  M. Labopin,et al.  Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  A. Hagemeijer,et al.  Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Ritz,et al.  Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  A. Nagler,et al.  Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity , 2006, Leukemia.

[29]  J. Esteve,et al.  Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) , 2005, Leukemia.

[30]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[31]  K. Sullivan,et al.  Long-Term Follow-Up of a Randomized Trial of Two Irradiation Regimens for Patients Receiving Allogeneic Marrow Transplants During First Remission of Acute Myeloid Leukemia , 1998 .

[32]  F. Appelbaum,et al.  Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. , 1990, Blood.